Jarvik 2000 左心室辅助装置作为心脏移植桥接:日本机械辅助循环支持注册研究
基于日本机械辅助循环支持注册数据库前瞻性收集13家医院数据,回顾83例接受Jarvik 2000植入作为移植桥接的患者,中位支持191天(最长758天);1年和2年总体生存比例分别为85.0%和79.3%,主要不良事件包括大出血、新发感染、卒中和装置故障,17例出现新发主动脉瓣反流。
要点
- 83例Jarvik 2000植入均为移植桥接,1年与2年总体生存比例分别为85.0%和79.3%。
- 常见不良事件为大出血27.7%、新发感染31.3%、卒中20.5%、装置故障20.5%。
- 17例出现新发主动脉瓣反流,其中6例随访期间至少达中度反流。
核心结论
- Jarvik 2000植入后中期生存令人满意,与其他国家和国际注册(INTERMACS和IMACS)报告的连续流左心室辅助装置相当。
- 尽管该装置具有间歇低速效应,仍出现新发主动脉瓣反流,部分受者在植入后2年内主动脉瓣反流进行性加重。
研究设计与样本
- 前瞻性收集日本机械辅助循环支持注册数据库中13家参与医院的数据,分析死亡、并发症及新发主动脉瓣反流。
- 回顾83例接受Jarvik 2000植入的患者,中位支持时间191天(最长758天),所有受者均以心脏移植为桥接目的植入。
主要发现
- 1年和2年总体生存比例分别为85.0%和79.3%。
- 9例患者为INTERMACS 1级,28例在植入时正在接受机械循环支持。
- 死亡原因包括卒中、感染和装置故障;3例移除装置,其中2例在心脏移植时、1例在左心室恢复后。
- 常见不良事件包括大出血27.7%、新发感染31.3%、卒中20.5%和装置故障20.5%。
- 17例观察到新发主动脉瓣反流,其中6例在随访期间至少发展为中度反流。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Jarvik 2000 ventricular assist device features a miniaturized intraventricular pump and an intermittent low-speed function that facilitates aortic valve opening. Despite its long history, little is known about the Jarvik device with regard to post-implantation outcomes. METHODS: Prospectively collected data from 13 participating hospitals were extracted from the Japanese Registry for Mechanically Assisted Circulatory Support database to analyze mortality, morbidity and de-novo aortic regurgitation. Data on 83 patients who underwent implantation of the Jarvik 2000 were reviewed. Median support duration was 191 (maximum 758) days. All recipients underwent implantation as a bridge to transplantation. RESULTS: Overall survival proportions at 1 and 2 years were 85.0% and 79.3%, respectively. Nine patients were in INTERMACS Level 1, and 28 patients were on mechanical circulatory support at the time of implantation. Causes of death included stroke, infection and device malfunction. Three patients had their device removed: 2 at the time of heart transplantation and 1 after recovery of the left ventricle. Common adverse events included major bleeding (27.7%), new infection (31.3%), stroke (20.5%) and device malfunction (20.5%). De-novo aortic regurgitation was observed in 17 patients, 6 of whom developed at least moderate regurgitation during follow-up. CONCLUSIONS: Mid-term survival after Jarvik 2000 implantation was satisfactory and comparable to that reported by other national and international registries (INTERMACS and IMACS) for continuous-flow LVADs. De novo aortic regurgitation occurred despite the intermittent low-speed effect of this device, with some recipients experiencing progressive worsening of aortic regurgitation within 2 years post-implantation.
引用
- Kohno H, Matsumiya G, Sawa Y, et al. The Jarvik 2000 left ventricular assist device as a bridge to transplantation: Japanese Registry for Mechanically Assisted Circulatory Support. J Heart Lung Transplant. 2017. PMID: 29129374. doi:10.1016/j.healun.2017.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。